Hypertrophic pachymeningitis and choroid plexitis in IgG-4 related disease
Citation Manager Formats
Make Comment
See Comments

Abstract
A 64-year-old male presented with a 6-month history of headache, progressive hearing loss, vertigo, nausea/vomiting, diplopia, and gait instability. Past medical history was significant for hypertension. He was treated with several courses of antibiotics (doxycycline and ceftriaxone) for recurrent sinusitis. Neurological examination was notable for horizontal nystagmus, left facial weakness, bilateral sensorineural hearing loss, hyperreflexia in bilateral upper and lower extremities, and gait ataxia. Extensive serum laboratory workup for infectious and inflammatory disorders was non-revealing, except for a slightly elevated IgG4 level of 87.5 mg/dL (normal range: 3.9 to 86.4 mg/dL). CT examination of chest, abdomen, and pelvis was unremarkable. Cerebrospinal fluid (CSF) analysis revealed the following: protein 112 mg/dl, glucose 66 mg/dl, and white blood cell 41/µl with a lymphocytic predominance. CSF cytology and comprehensive infectious workup including meta-genomic next-generation sequencing was negative. Brain MRI with gadolinium contrast showed diffuse pachymeningeal thickening with enhancement, an enhancing mass in the choroid plexus of the posterior left lateral ventricle and focally enlarged choroid plexus within the fourth ventricle extending through the bilateral foramen of Luschka into the cerebellopontine cisterns (Figure 1). A right frontal dural biopsy showed prominent fibrosis and inflammation with CD3 positive T lymphocytes, CD20 positive B lymphocytes, and CD138 positive plasma cells (Figure 2). Strong IgG4 staining was observed with >100 IgG4 staining cells in one high power microscopic field and an IgG4/IgG staining ratio of >40% (Figure 2). A diagnosis of IgG4-related central nervous system (CNS) disorder involving predominantly the pachymeninges and choroid plexus was made. Treatment of intravenous methylprednisolone, followed by oral prednisone 60 mg and rituximab was initiated, which led to clinical and radiographic improvement at 2 months. At 14 months follow-up, he was asymptomatic with a normal neurological examination, and repeat brain MRI revealed significant improvement of pachymeningeal and choroidal thickening and enhancement (Figure 1).
- Received June 8, 2020.
- Accepted August 21, 2020.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
The Nerve!: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.